IDEAYA Biosciences, Inc.
IDYA
Price:
$37.12
Market Cap:
$3.14B
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patie...[Read more]
Industry
Biotechnology
IPO Date
2019-05-23
Stock Exchange
NASDAQ
Ticker
IDYA
The ROE as of September 2024 (TTM) for IDEAYA Biosciences, Inc. (IDYA) is -20.53%
According to IDEAYA Biosciences, Inc.’s latest financial reports and current stock price. The company's current ROE is -20.53%. This represents a change of 295.41% compared to the average of -5.19% of the last 4 quarters.
IDEAYA Biosciences, Inc. (IDYA) Historical ROE (quarterly & annually)
How has IDYA ROE performed in the past?
The mean historical ROE of IDEAYA Biosciences, Inc. over the last ten years is 5.91%. The current -20.53% ROE has changed -447.56% with respect to the historical average. Over the past ten years (40 quarters), IDYA's ROE was at its highest in in the December 2018 quarter at 17.49%. The ROE was at its lowest in in the March 2018 quarter at -55.46%.
Average
5.91%
Median
-15.76%
Minimum
-38.29%
Maximum
75.37%
IDEAYA Biosciences, Inc. (IDYA) ROE by Quarter and Year
Discovering the peaks and valleys of IDEAYA Biosciences, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 15.96%
Maximum Annual ROE = 75.37%
Minimum Annual Increase = -154.57%
Minimum Annual ROE = -38.29%
| Year | ROE | Change |
|---|---|---|
| 2023 | -18.19% | 15.96% |
| 2022 | -15.68% | -0.51% |
| 2021 | -15.76% | -3.13% |
| 2020 | -16.27% | -57.50% |
| 2019 | -38.29% | -154.57% |
| 2018 | 70.17% | -6.90% |
IDEAYA Biosciences, Inc. (IDYA) Average ROE
How has IDYA ROE performed in the past?
The current ROE of IDEAYA Biosciences, Inc. (IDYA) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-16.55%
5-year avg
-20.84%
10-year avg
5.91%
IDEAYA Biosciences, Inc. (IDYA) ROE vs. Peers
How is IDYA’s ROE compared to its peers?
IDEAYA Biosciences, Inc.’s ROE is greater than AnaptysBio, Inc. (-255.67%), greater than MeiraGTx Holdings plc (-86.28%), greater than Keros Therapeutics, Inc. (-44.73%), greater than Homology Medicines, Inc. (-100.91%), greater than Ventyx Biosciences, Inc. (-61.43%), less than Protagonist Therapeutics, Inc. (85.47%), greater than Verona Pharma plc (-55.46%), greater than Syndax Pharmaceuticals, Inc. (-57.42%), greater than Cerevel Therapeutics Holdings, Inc. (-98.94%), greater than Avidity Biosciences, Inc. (-32.89%), greater than Revolution Medicines, Inc. (-34.57%), greater than Day One Biopharmaceuticals, Inc. (-122.70%), greater than SpringWorks Therapeutics, Inc. (-56.13%), greater than Terns Pharmaceuticals, Inc. (-39.58%), greater than Acumen Pharmaceuticals, Inc. (-24.63%), greater than Amylyx Pharmaceuticals, Inc. (-46.15%), greater than MoonLake Immunotherapeutics (-11.05%), less than X4 Pharmaceuticals, Inc. (32.93%), greater than Inozyme Pharma, Inc. (-68.93%), greater than VectivBio Holding AG (-56.92%),
| Company | ROE | Market cap |
|---|---|---|
| -255.67% | $1.17B | |
| -86.28% | $325.85M | |
| -44.73% | $2.09B | |
| -100.91% | $3.02M | |
| -61.43% | $161.48M | |
| 85.47% | $2.74B | |
| -55.46% | $2.43B | |
| -57.42% | $1.54B | |
| -98.94% | $8.19B | |
| -32.89% | $4.90B | |
| -34.57% | $7.38B | |
| -122.70% | $1.21B | |
| -56.13% | $2.64B | |
| -39.58% | $665.01M | |
| -24.63% | $153.20M | |
| -46.15% | $181.10M | |
| -11.05% | $3.19B | |
| 32.93% | $120.06M | |
| -68.93% | $373.90M | |
| -56.92% | $1.06B |
Build a custom stock screener for IDEAYA Biosciences, Inc. (IDYA) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like IDEAYA Biosciences, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
IDEAYA Biosciences, Inc. (IDYA) and other stocks custom spreadsheet templates
The easiest way to analyze a company like IDEAYA Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is IDEAYA Biosciences, Inc.'s ROE?
How is the ROE calculated for IDEAYA Biosciences, Inc. (IDYA)?
What is the highest ROE for IDEAYA Biosciences, Inc. (IDYA)?
What is the 3-year average ROE for IDEAYA Biosciences, Inc. (IDYA)?
What is the 5-year average ROE for IDEAYA Biosciences, Inc. (IDYA)?
How does the current ROE for IDEAYA Biosciences, Inc. (IDYA) compare to its historical average?